Scalable Bioprocess for rAAV Production using a HeLa Stable Cell Line
iBET’s scientific article “Towards a scalable bioprocess for rAAV production using a HeLa stable cell line” was ranked among the Top 10% Most-viewed articles in Biotechnology and Bioengineering in 2023.
The study outlines a streamlined scalable approach for recombinant adeno-associated viruses (rAAVs) production, using a HeLaS3-based stable cell line.
Key highlights include:
- Rapid cell line generation (3-4 months);
- Bulk rAAV titers > 3×1011 vg/mL;
- Good product quality (full to empty capsids ratio > 70%);
- Efficient process-related impurities elimination;
- Purified rAAV yields > 1×1011 vg/mL.
This platform provides a promising solution to scalability challenges and the high cost of raw materials that currently impact rAAV manufacturing.
iBET acknowledges the journal and broader scientific community for the recognition and engagement with our work. Congratulations to the authors: José Escandell, Filipa Moura, Sofia Carvalho, Ricardo Silva, Ricardo Correia, António Roldão, Patrícia Gomes-Alves and Prof. Paula Alves.
